Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 13Glioblastoma 7Sarcoma 3Glioma 3Brain Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Astrocytoma 2Urothelial Carcinoma of the Bladder 1Prostatic Hyperplasia 1Pathologic Complete Response 1Paranasal Sinus Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Muscle-invasive Urothelial Cancer of the Bladder 1Mouth Neoplasms 1Lymphoma, Follicular 1Lung Neoplasms 1Laryngeal Neoplasms 1Giant Cell Tumor of Bone 1Ganglioneuroblastoma 1Estrogen Receptor Positive Breast Cancer 1Ependymoma 1Craniopharyngioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 55Carboplatin 49pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11Sunitinib 10Platinum 10130-nm albumin-bound paclitaxel 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Transurethral Resection of Bladder × Clear all
NCT06980038 2026-05-13

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡